CHILDRENS CANCER GROUP

儿童癌症组

• 批准号: 2007313
• 负责人: CHRISTOPHER J FRYER
• 金额: $ 7.76万
• 依托单位: UNIVERSITY OF BRITISH COLUMBIA
• 依托单位国家: 美国
• 财政年份: 1981
• 资助国家: 美国
• 起止时间: 1981-07-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2007313
• 关键词: Hodgkin's disease; adolescence (12-20); bone marrow purging; bone marrow transplantation; brain neoplasms; child (0-11); clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; human subject; human therapy evaluation; leukemia; liver neoplasms; longitudinal human study; neoplasm /cancer chemotherapy; neoplasm /cancer epidemiology; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neuroblastoma; pediatric neoplasm /cancer; radiation carcinogenesis; sarcoma; young adult human (21-34)

The Pediatric Oncology Division of the University of British Columbia, Vancouver, Canada has a strong commitment to participate fully in all CCG activities. The Division has enjoyed full memberships since 1974 and funding since 1980. Despite being a single institution without affiliates, there has been a steady increase in patient entry onto CCG therapeutic studies from 35 in 1987 - 1988, to 60 in the period 8/1/91 to 7/31/92. The Division has developed a comprehensive cancer program that serves the needs of all children in British Columbia. In addition, the institute is recognized by CCG as a transplant center and provides bone marrow transplantations to patients from Canadian provinces that may be on CCG protocols. In addition to children seen at BC's Children's Hospital, patients aged 15 to 30 years, who are eligible, seen at the BC Cancer Agency are also entered onto specific CCG protocols. As a University affiliated institution, the Division has responsibllities for research and education. The Division is recognized as one of only three fellowship training centers in Canada for pediatric hematology/oncology. Members of the Division hold key committee and administrative leadership roles and have been active in the formulation and implementation of research proposals for CCG including data analysis and presentation of results. Whilst two senior members of the Division resigned this year, (Dr. P. Rogers and Dr. K. W. Chan), the Division has been able to expand its membership with three new investigators: Dr. J. H. Davis, Dr. K. Schultz, and Dr. R. Anderson, all of whom have had prior oncologic experience and cooperative group activities and are assuming CCG committee roles. Dr. Kirk Schultz was appointed to CCO 1921 in January 1993. Professor Skala and the research section of the Division is evaluating marrow purging techniques in acute lymphatic leukemia and neuroblastoma. Dr. Schultz is developing a murine system to research the etiological factors in GVH. Mary McBride is co-investigator of the cross-Canadian epidemiology study in ALL addressing the significance of electromagnetic field exposure. Dr. Blair has developed a murine model system evaluating the effect of timing of chemotherapy on liver regeneration following surgical resection. There is a comprehensive multi-disciplinary clinic to evaluate the late effects of cancer therapy which continues to monitor patients through adulthood by the B.C. Cancer Agency. We have not been able to enter patients onto the randomized arm of the CCG neuroblastoma 3891 since the government funded health care system will not cover the cost of research transplantation on this protocol.

不列颠哥伦比亚大学的儿科肿瘤科， 加拿大温哥华有坚定的承诺能够充分参与所有CCG 活动。自1974年以来，该部门一直享有完整的会员资格。 自1980年以来的资金。尽管是一个没有分支机构的机构，但 患者进入CCG治疗量已经稳定增加 从1987年至1988年的35个研究，到8/1/91到7/31/92的60。这 部门已经制定了一项全面的癌症计划，该计划为 不列颠哥伦比亚省所有儿童的需求。此外，研究所是 被CCG识别为移植中心并提供骨髓 向可能正在CCG上的加拿大省份的患者移植 协议。 除了在卑诗省儿童医院看到的儿童外，15岁的患者 在卑诗省癌症局中看到的符合条件的30年也是 输入特定的CCG协议。作为一所大学 机构，该部门具有研究和教育的责任。 该部门被认为是仅有的三个奖学金培训之一 加拿大的小儿血液学/肿瘤学中心。成员 部门担任关键委员会和行政领导职务，并具有 一直积极进行研究建议的制定和实施 对于CCG，包括数据分析和结果呈现。而两个 该部门的高级成员今年辞职（P. Rogers博士和博士。 K. W. Chan），该部门能够扩大其成员资格 三名新调查人员：J。H. Davis博士，K。Schultz博士和R.博士。 安德森（Anderson），所有人都有事先的肿瘤学经验和合作社 小组活动，并承担CCG委员会的角色。柯克·舒尔茨（Kirk Schultz）博士 于1993年1月被任命为CCO 1921。 Skala教授和该部门的研究部分正在评估 急性淋巴白血病和神经母细胞瘤中的骨髓清除技术。 舒尔茨博士正在开发一种鼠系统来研究病因 GVH中的因素。玛丽·麦克布赖德（Mary McBride）是跨加拿大人的共同研究者 流行病学研究都解决了电磁的重要性 现场曝光。布莱尔博士已经开发了一种评估鼠模型系统 化学疗法时间对肝脏再生的影响 手术切除。有一个全面的多学科诊所 评估癌症治疗的后期作用，该疗法继续监测 卑诗省成年的患者癌症代理。我们还没有 能够将患者输入CCG神经母细胞瘤的随机臂上 3891由于政府资助的医疗保健系统将不涵盖 该协议的研究移植成本。